The Importance of Testosterone Control in Prostate Cancer

European Urology, Supplements

Volumn 6, Issue 15, 2007, Pages 834-839

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Hormone therapy; Luteinising hormone releasing hormone agonist; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANTIANDROGEN; BUSERELIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TESTOSTERONE; TRIPTORELIN;

ANEMIA; APOPTOSIS; CANCER INCIDENCE; CASTRATION; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INHIBITION; DRUG SCREENING; GYNECOMASTIA; HISTORY OF MEDICINE; HOMEOSTASIS; HOT FLUSH; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LIBIDO DISORDER; MEDICAL LITERATURE; MEDICAL SOCIETY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34547118594     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.06.002     Document Type: Review

References (47)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Vela I., Gregory L., Gardiner E.M., Clements J.A., and Nicol D.L. Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int 99 (2006) 735-742
3. Oefelein M.G., and Resnick M.I. Effective testosterone suppression for patients with prostate cancer: is there a best castration?. Urology 62 (2003) 207-213
4. Available at: http://www.uroweb.org/nc/professional-resources/guidelines/online/. Accessed on 24 July 2007.
5. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 (2007) 1596-1605
6. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
7. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
8. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-108
9. D'Amico A.V., Loffredo M., Renshaw A.A., Loffredo B., and Chen M.H. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190-4195
10. Schalken J.A. Apoptosis in the human prostate. Drugs Today (Barc) 37 Suppl D (2001) 23-26
11. Denmeade S.R., Lin X.S., and Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28 (1996) 251-265
12. Schalken J. Androgen receptor mediated growth of prostate (cancer). Eur Urol Suppl 4 8 (2005) 4-11
13. Isaacs J.T., and Isaacs W.B. Androgen receptor outwits prostate cancer drugs. Nat Med 10 (2004) 26-27
14. Litvinov I.V., De Marzo A.M., and Isaacs J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J Clin Endocrinol Metab 88 (2003) 2972-2982
15. Gao J., Arnold J.T., and Isaacs J.T. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61 (2001) 5038-5044
16. Denmeade SR, Tombal B, Isaacs JT. Apoptotic pathways in prostate cancer. In: A volume II, programmed cell death: role in disease, pathogenesis, and prevention. 1999.
17. Niehans P. Prostata-Krebs wie paraprostata-hypertrophie sind folgen hormonaler störungen, die wir je früher je besser beeinflussen können. 1940.
18. Huggins C., Stevens R., and Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
19. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
20. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
21. Oefelein M.G., Feng A., Scolieri M.J., Ricchiutti D., and Resnick M.I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 (2000) 1021-1024
22. Kaisary A.V., Tyrrell C.J., Peeling W.B., and Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67 (1991) 502-508
23. Lin B.J.T., Chen K.K., Chen M.T., and Chang L.S. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 43 (1994) 834-837
24. Rohl H.F., and Beuke H.P. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 26 (1992) 11-14
25. Tombal B., Jasienski S., Debie B., Salvado Besnier J.A., and van Cangh P. Is there a significant difference in testosterone level after surgical castration, goserelin or triptorelin?. Eur Urol Suppl 6 (2007) 87 (abstract no. 260)
26. Vogelzang N.J., Chodak G.W., Soloway M.S., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46 (1995) 220-226
27. Zlotta A.R., Abrahamsson P.-A., Tombal B., Berges R., and Debruyne F. Hormone therapy: improving therapy decisions and monitoring. Eur Urol Suppl 5 (2006) 369-376
28. Labrie F., Bélanger A., Luu-The V., et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26 (2005) 361-379
29. Periti P., Mazzei T., and Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 41 (2002) 485-504
30. Kaku H., Saika T., Tsushima T., et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66 (2006) 439-444
31. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212-8218
32. Calais Da Silva F.M., Calais Da Silva F., Bono A., et al. Phase III intermittent MAB vs continuous MAB. J Clin Oncol 24 (2006) 220 (abstract no. 4513)
33. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 Suppl 1 (2007) 19-22
34. Cassileth B.R., Soloway M.S., Vogelzang N.J., et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1 (1992) 323-329
35. Morote J., Esquena S., Abascal J.M., et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 77 (2006) 135-138
36. Sarosdy M.F., Schellhammer P.F., Soloway M.S., et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (1999) 801-806
37. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726-729
38. Wechsel H.W., Zerbib M., Pagano F., and Coptcoat M.J. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 30 Suppl 1 (1996) 7-14
39. McLeod D., Zinner N., Tomera K., et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58 (2001) 756-761
40. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 60 Suppl 2 (1998) 18-24
41. Perachino M., Cavalli V., and Ferraris V. Do all patients receiving LHRH therapy for advanced prostate cancer achieve castrate levels of testosterone? Results of a prospective study on 105 patients. Eur Urol Suppl 6 (2007) 87 (abstract no. 258)
42. Kawakami J., and Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 167 Suppl (2002) 288 (abstract no. 1135)
43. Sharifi R., and Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 168 (2002) 1001-1004
44. Zlotta A., and Debruyne F.M.J. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 4 8 (2005) 37-41
45. Fontana D., Mari M., Martinelli A., et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 70 (2003) 316-320
46. Khan M.S., and O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 60 (1998) 33-40
47. Morote J., Planas J., Raventos C.X., et al. The serum testosterone castration level with clinical relevance. Eur Urol Suppl 6 (2007) 29 (abstract no. 25)